CRB INNOVATION IS BASED ON A METABOLIC APPROACH AS THE ROOT CAUSE OF CANCER
Many theories have emerged to explain the root cause of cancer. The somatic mutation hypothesis depicts DNA mutations as the first and main cause of cancer initiation. The Warburg theory describes the mitochondrial metabolic pathways as the upstream mechanisms that lead to DNA mutations, which in turn leads to cancer. In other words, environmental factors affect other parts of the cell, such as mitochondria, before reaching the DNA.
If we can keep mitochondria in balance, we can protect DNA from developing irreversible mutations that lead to severe diseases, including cancer.
At CRB, we aim to treat cancer patients by restoring the metabolic functions of the cell. This will help to eradicate cancer cells, reduce the metastatic spreading of tumors, and avoid cancer recurrence.
OUR FIRST DRUG IS FOR TRIPLE NEGATIVE BREAST CANCER
Triple Negative Breast Cancer (TNBC) is a very aggressive form of breast cancer that constitutes 15-20% of all breast cancer cases. It lacks three main factors (triple negative): estrogen receptors, progesterone receptors, and HER2 protein. It affects young women and mothers, especially when carrying a BRCA1 mutation. TNBC has a high metastatic rate with few and limited treatment options.
PRE-CLINICAL TRIALS
CRB091 IN TNBC TREATMENT:
PRE-CLINICAL TRIALS
CRB’s first oncology drug, CRB091, targets TNBC tumors by selectively eradicating cancer cells, without inducing toxicity in healthy organs. The pre-clinical research of CRB091 showed significant results on human cancer cell lines in both efficacy and safety.
CRB has drawn a clear path to first in-human, and will soon launch clinical trials phase I and II.
